Popular
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 3
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch.1
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch.1
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
Treatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
CardiologyTreatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
Andrew Patrick Ambrosy, MD, MPH
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
CardiologySPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
Muthiah Vaduganathan, MD, MPH
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
CME/CEChairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Jean Hoffman-Censits, MD
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
CME/CEGrooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Pam R. Taub, MD, FACC, FASPC
Programs
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual EventPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 4
Modern AestheticsRF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 4
Konika Patel Schallen, MD
Gilly Munavalli, MD
James Newman, MD, FACS
Scott Gerrish, DO
Sara Hogan, MD, FAAD
Cameron Rokhsar, MD
Finerenone in HFpEF: Key Insights From ESC HF
CardiologyFinerenone in HFpEF: Key Insights From ESC HF
John W. Ostrominski, MD, MPH
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
CME/CEGrooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Pam R. Taub, MD, FACC, FASPC
The OD As a Salesperson + the Ocular Side of Oncology
Modern OptometryThe OD As a Salesperson + the Ocular Side of Oncology
Cecelia Koetting, OD, FAAO
Face Value with Modern Aesthetics: Review of Global Aesthetics Market Analysis
Modern AestheticsFace Value with Modern Aesthetics: Review of Global Aesthetics Market Analysis
Clinical Practice
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
CardiologySPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
Muthiah Vaduganathan, MD, MPH
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CEFXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC
Ashkan Shoamanesh, MD
Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Sjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
CME/CESjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
Chadwick R. Johr, MD
Doctors Lounge
Navigating Vaccine Communication: A Medical Affairs Perspective
MAPSChatsNavigating Vaccine Communication: A Medical Affairs Perspective
Matt Birnholz, MD
Abigail Sporer, PhD, MBA
“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
The Convergence“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
Brian P. McDonough, MD, FAAFP
Rajiv Kumar, MD
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
Matt Birnholz, MD
Brandon Young, PhD
Designing Smarter Insight Frameworks in Medical Affairs
MAPSChatsDesigning Smarter Insight Frameworks in Medical Affairs
Matt Birnholz, MD
Tony Page
Turning Insight into Action: The Expanding Role of Medical Affairs
MAPSChatsTurning Insight into Action: The Expanding Role of Medical Affairs
Matt Birnholz, MD
Michael DeLuca, PharmD, MBA, MSRA
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
Ryan Quigley
Samuel Muench, MD
CME
Movements With Meaning: Reading the Pattern, Not the Label
CME/CEMovements With Meaning: Reading the Pattern, Not the Label
Karen E. Anderson, MD
Hubert H. Fernandez, MD
Case Challenges in Systemic Mastocytosis: Clinical Insights From the Expert Roundtable
CME/CECase Challenges in Systemic Mastocytosis: Clinical Insights From the Expert Roundtable
Carole Bitar, MD, FAAD
Matthew P. Giannetti, MD
Benjamin Ungar, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
NephrologyOptimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
CME/CEPrecision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
Harry Erba, MD, PhD
Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
CME/CEChairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
Kathleen N. Moore, MD, MS
VMAT2 in the Real World: Recently Presented Clinical Data That Should Change TD Practice
MinuteCE®VMAT2 in the Real World: Recently Presented Clinical Data That Should Change TD Practice
Industry Feature
Advancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Medical Industry FeatureAdvancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Jennifer Caudle, DO, FACOFP
Seth Wander, MD, PhD
Identifying and Managing Adult Patients with Chronic Immune Thrombocytopenia
Medical Industry FeatureIdentifying and Managing Adult Patients with Chronic Immune Thrombocytopenia
Sandhya Panch, MD, MPH
Ocular Management in PROC: Insights on Collaborative Care Across Practice Settings
Project Oncology®Ocular Management in PROC: Insights on Collaborative Care Across Practice Settings
Jennifer Caudle, DO, FACOFP
Ida Micaily, MD
Jeffrey Varanelli, OD
Evolving Treatment Approaches in EGFRm NSCLC
Medical Industry FeatureEvolving Treatment Approaches in EGFRm NSCLC
Jennifer Caudle, DO, FACOFP
Hossein Borghaei, MS, DO
Debunking Five Misconceptions in Agitation in Alzheimer’s Dementia
Medical Industry FeatureDebunking Five Misconceptions in Agitation in Alzheimer’s Dementia
Clay Jackson, MD
Amita Patel, MD, CMD
BRCA and HRD Biomarker Testing in Advanced Ovarian Cancer: A KOL Panel Discussion
Medical Industry FeatureBRCA and HRD Biomarker Testing in Advanced Ovarian Cancer: A KOL Panel Discussion
Sharyn N. Lewin, MD, FACS, FACOG
Dana Chase, MD